A multicentre randomised trial in Germany comparing spinal with general anaesthesia in older adults undergoing hip fracture surgery found no clinically meaningful difference in serious postoperative complications. The trial was terminated early, leaving modest statistical power and substantial treatment crossover, so the results are best read as supportive rather than definitive. The evidence favours selecting the anaesthetic technique according to individual patient characteristics rather than applying a categorical preference.
Key Points
- No meaningful difference in serious complications between spinal and general anaesthesia
- Trial ended early with modest power and high crossover
- Evidence supports individualised anaesthetic selection in older hip fracture patients
Longevity Analysis
Hip fracture in later life is a pivotal event in the trajectory of healthspan, where surgical stress, immobilisation, and postoperative delirium can permanently alter functional independence. Removing anaesthetic modality as a presumed determinant of outcome redirects attention to the factors that genuinely shape recovery: preoperative reserve, time to surgery, pain control, cognitive vulnerability, and how quickly weight-bearing and rehabilitation resume. For the ageing patient, the durable advantage lies less in which technique is chosen than in how carefully the plan is matched to the individual and how consistently early mobilisation is executed.
Original published by The Lancet Healthy Longevity, by Ana Kowark, Stefanie Schoenen, Rene Schmidt, Haris Zubanovic, Leila Elammari, Axana Engelhardt, Christoph Ilies, Jonas Keuler, Friedrich K Pühringer, Verena May, Christian Minarski, Tobias Malisi, Simon Diepold, Thomas Saller, Daniel Chappell, Simon T Schaefer, Roland Tomasi, Richard K Ellerkmann, Jens-Peter Stahl, Stefan Walther, Barbara Reinartz, Markus H Huppertz-Thyssen, Marcel Poels, Christian Adam, Andreas Hohn, Hans-Peter Reiffen, Volker Gebhardt, Dietrich Henzler, Linda Grüßer, Sebastian Goldmann, Dieter C Wirtz, Stephanie Wied, Mark Coburn, iHOPE Study group.